First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine BaudeletGérard Zalcman

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint Dive into the research topics of 'First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences